Heart Attack

SpectraCell Laboratories Offers Additional Test for Heart Attack and Stroke Risk

Published in Lab Business Week, July 27th, 2008

SpectraCell Laboratories has added an innovative blood test called Lp-PLA2 (Lipoprotein-associated Phospholipase A2) to its arsenal of advanced cardiovascular testing aimed at early detection of cardiovascular disease. The new test measures the amount of a specific enzyme in blood that occurs when there is an active atherosclerotic process that could lead to the rupture of plaque and cause a heart attack or stroke.

Lipid measurement and cardiac imaging cannot identify which patients have rupture-prone plaque with thin fibrous caps. Therefore, finding serologic markers with high specificity for advanced plaque is a useful diagnostic tool in cardiovascular risk...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2008-07-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry